Cardiff Oncology, Inc. (CRDF): Revenue
$593.0K
Year ended 2025-12-31
$508.0K
Trailing 12 months to 2026-06-30
+15.4%
3-year compound annual growth
+10.1%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $593.0K | -13.2% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $683.0K | +40.0% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $488.0K | +26.4% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $386.0K | +7.5% | 2024-02-29, From 2022-01-01 |
| 2021-12-31 | $359.0K | -1.9% | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | $366.0K | n/a | 2022-02-24, From 2020-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $593.0K | -13.2% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $800.0K | -77.1% |
| Prokidney Corp. (PROK) | 2025-12-31 | $893.0K | n/m |
| Pluri Inc. (PLUR) | 2026-06-30 | $1.02M | -24.0% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $1.30M | +550.0% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $1.31M | +99.2% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $1.41M | n/a |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $190.0K | -19.1% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $2.04M | n/a |
Compare CRDF, IMA, PROK, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗